{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T06:22:41Z","timestamp":1792736561568,"version":"4.5.0"},"reference-count":240,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100015920","name":"Guangxi University of Science and Technology","doi-asserted-by":"publisher","award":["2023BZRC014"],"award-info":[{"award-number":["2023BZRC014"]}],"id":[{"id":"10.13039\/501100015920","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004607","name":"Natural Science Foundation of Guangxi Province","doi-asserted-by":"publisher","award":["2024GXNSFBA010423"],"award-info":[{"award-number":["2024GXNSFBA010423"]}],"id":[{"id":"10.13039\/501100004607","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004607","name":"Natural Science Foundation of Guangxi Province","doi-asserted-by":"publisher","award":["2023GXNSFAA026039"],"award-info":[{"award-number":["2023GXNSFAA026039"]}],"id":[{"id":"10.13039\/501100004607","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32560218"],"award-info":[{"award-number":["32560218"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.autrev.2026.104029","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T17:00:17Z","timestamp":1773075617000},"page":"104029","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Precision immunotherapies for systemic lupus erythematosus: From pathogenic targets to translational horizons"],"prefix":"10.1016","volume":"25","author":[{"given":"Chenjing","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuqing","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengcheng","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2026.104029_bb0005","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/ard-2022-223035","article-title":"Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study","volume":"82","author":"Tian","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104029_bb0010","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104029_bb0015","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1136\/ard-2022-223741","article-title":"Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets","volume":"82","author":"Crow","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104029_bb0020","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41584-021-00668-1","article-title":"Global epidemiology of systemic lupus erythematosus","volume":"17","author":"Barber","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2026.104029_bb0025","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1136\/annrheumdis-2022-222276","article-title":"Rising incidence and prevalence of systemic lupus erythematosus: a population-based study over four decades","volume":"81","author":"Duarte-Garc\u00eda","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104029_bb0030","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.3899\/jrheum.080912","article-title":"The 1000 Canadian faces of lupus: determinants of disease outcome in a large multiethnic cohort","volume":"36","author":"Peschken","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2026.104029_bb0035","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/annrheumdis-2020-218338","article-title":"Proteomic, biomechanical and functional analyses define neutrophil heterogeneity in systemic lupus erythematosus","volume":"80","author":"Bashant","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104029_bb0040","doi-asserted-by":"crossref","first-page":"9813","DOI":"10.1073\/pnas.0909927107","article-title":"Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis","volume":"107","author":"Hakkim","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2026.104029_bb0045","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abo5840","article-title":"ATR-mediated DNA damage responses underlie aberrant B cell activity in systemic lupus erythematosus","volume":"8","author":"Manolakou","year":"2022","journal-title":"Sci Adv"},{"key":"10.1016\/j.autrev.2026.104029_bb0050","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1172\/JCI78001","article-title":"Defective removal of ribonucleotides from DNA promotes systemic autoimmunity","volume":"125","author":"G\u00fcnther","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2026.104029_bb0055","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/nm.4027","article-title":"Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease","volume":"22","author":"Lood","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2026.104029_bb0060","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1084\/jem.20151876","article-title":"Oxidized mitochondrial nucleoids released by neutrophils drive type I interferon production in human lupus","volume":"213","author":"Caielli","year":"2016","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2026.104029_bb0065","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.613597","article-title":"Deoxyribonuclease 1-mediated clearance of circulating chromatin prevents from immune cell activation and pro-inflammatory cytokine production, a phenomenon amplified by low Trap1 activity: consequences for systemic lupus erythematosus","volume":"12","author":"Felux","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104029_bb0070","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/s41586-020-2282-0","article-title":"TASL is the SLC15A4-associated adaptor for IRF5 activation by TLR7-9","volume":"581","author":"Heinz","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2026.104029_bb0075","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/intimm\/dxab006","article-title":"Human SLC15A4 is crucial for TLR-mediated type I interferon production and mitochondrial integrity","volume":"33","author":"Kobayashi","year":"2021","journal-title":"Int Immunol"},{"key":"10.1016\/j.autrev.2026.104029_bb0080","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.cellimm.2014.12.002","article-title":"TLR7, IFN\u03b3, and T-bet: their roles in the development of ABCs in female-biased autoimmunity","volume":"294","author":"Rubtsova","year":"2015","journal-title":"Cell Immunol"},{"key":"10.1016\/j.autrev.2026.104029_bb0085","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.immuni.2019.12.005","article-title":"Distinct effector B cells induced by unregulated toll-like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus","volume":"52","author":"Jenks","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.autrev.2026.104029_bb0090","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.cell.2010.02.021","article-title":"Th17 and regulatory T cells in mediating and restraining inflammation","volume":"140","author":"Littman","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.autrev.2026.104029_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102668","article-title":"Phoenix from the flames: rediscovering the role of the CD40-CD40L pathway in systemic lupus erythematosus and lupus nephritis","volume":"19","author":"Ramanujam","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2026.104029_bb0100","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1136\/annrheumdis-2012-202322","article-title":"Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS study)","volume":"72","author":"Costedoat-Chalumeau","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104029_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2023.101873","article-title":"Systemic lupus erythematosus and glucocorticoids: a never-ending story?","volume":"37","author":"Paredes-Ruiz","year":"2023","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.autrev.2026.104029_bb0110","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1080\/08860220802353843","article-title":"Mycophenolate mofetil versus azathioprine in the maintenance therapy of lupus nephritis","volume":"30","author":"Sahin","year":"2008","journal-title":"Ren Fail"},{"key":"10.1016\/j.autrev.2026.104029_bb0115","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/rheumatology\/kez279","article-title":"Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a phase III study extension","volume":"59","author":"van Vollenhoven","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2026.104029_bb0120","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1136\/ard-2023-224854","article-title":"Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial","volume":"83","author":"Wu","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104029_bb0125","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJMoa2410965","article-title":"Efficacy and safety of Obinutuzumab in active lupus nephritis","volume":"392","author":"Furie","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104029_bb0130","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti-interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis & Rheumatism"},{"key":"10.1016\/j.autrev.2026.104029_bb0135","article-title":"Allogeneic CD19-targeted CAR-T therapy in refractory systemic lupus erythematosus achieved durable remission","author":"Wang","year":"2025","journal-title":"Med"},{"key":"10.1016\/j.autrev.2026.104029_bb0140","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2026.104029_bb0145","doi-asserted-by":"crossref","first-page":"5084","DOI":"10.1016\/j.cell.2023.10.001","article-title":"Chimeric autoantibody receptor T cells deplete NMDA receptor-specific B cells","volume":"186","author":"Reincke","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.autrev.2026.104029_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e19763","article-title":"Engineering chimeric autoantibody receptor T cells for targeted B cell depletion in multiple sclerosis model: an in-vitro study","volume":"9","author":"Sahlolbei","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.autrev.2026.104029_bb0155","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25084226","article-title":"Precise targeting of autoantigen-specific B cells in lupus nephritis with chimeric autoantibody receptor T cells","volume":"25","author":"Sol\u00e9","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2026.104029_bb0160","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1002\/art.39559","article-title":"Enhanced tyrosine phosphatase activity underlies dysregulated B cell receptor signaling and promotes survival of human lupus B cells","volume":"68","author":"Fleischer","year":"2016","journal-title":"Arthritis & Rheumatism"},{"key":"10.1016\/j.autrev.2026.104029_bb0165","doi-asserted-by":"crossref","first-page":"73ps79","DOI":"10.1126\/scitranslmed.3002138","article-title":"Dissecting the immune cell mayhem that drives lupus pathogenesis","volume":"3","author":"Craft","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.autrev.2026.104029_bb0170","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1056\/NEJMoa021933","article-title":"Development of autoantibodies before the clinical onset of systemic lupus erythematosus","volume":"349","author":"Arbuckle","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104029_bb0175","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.cytogfr.2013.04.003","article-title":"The BAFF\/APRIL system: emerging functions beyond B cell biology and autoimmunity","volume":"24","author":"Vincent","year":"2013","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.autrev.2026.104029_bb0180","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20246231","article-title":"B cell abnormalities in systemic lupus erythematosus and lupus nephritis-role in pathogenesis and effect of immunosuppressive treatments","volume":"20","author":"Yap","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2026.104029_bb0185","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1073\/pnas.95.8.4504","article-title":"Immune regulation by the ST6Gal sialyltransferase","volume":"95","author":"Hennet","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2026.104029_bb0190","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3109\/08830185.2012.709890","article-title":"CD22 and autoimmune disease","volume":"31","author":"D\u00f6rner","year":"2012","journal-title":"Int Rev Immunol"},{"key":"10.1016\/j.autrev.2026.104029_bb0195","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1007\/s13238-018-0509-8","article-title":"Transmembrane domain dependent inhibitory function of Fc\u03b3RIIB","volume":"9","author":"Wang","year":"2018","journal-title":"Protein Cell"},{"key":"10.1016\/j.autrev.2026.104029_bb0200","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22052424","article-title":"Dysregulated CD38 expression on peripheral blood immune cell subsets in SLE","volume":"22","author":"Burns","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2026.104029_bb0205","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s13075-023-03203-7","article-title":"Differential expression pattern of Bcl-2 family members in B and T cells in systemic lupus erythematosus and rheumatoid arthritis","volume":"25","author":"Kielbassa","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2026.104029_bb0210","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1084\/jem.194.12.1823","article-title":"BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha\/beta induction","volume":"194","author":"Dzionek","year":"2001","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2026.104029_bb0215","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.0050248","article-title":"BDCA2\/fc epsilon RI gamma complex signals through a novel BCR-like pathway in human plasmacytoid dendritic cells","volume":"5","author":"Cao","year":"2007","journal-title":"PLoS Biol"},{"key":"10.1016\/j.autrev.2026.104029_bb0220","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11926-996-0065-8","article-title":"T cells in the pathogenesis of systemic lupus erythematosus: potential roles of CD154-CD40 interactions and costimulatory molecules","volume":"2","author":"Yellin","year":"2000","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.autrev.2026.104029_bb0225","doi-asserted-by":"crossref","DOI":"10.3390\/cells13191621","article-title":"Implications of CD154 and its receptors in the pathogenesis and treatment of systemic lupus erythematosus","volume":"13","author":"Allard","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.autrev.2026.104029_bb0230","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1172\/JCI200319301","article-title":"Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions","volume":"112","author":"Grammer","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2026.104029_bb0235","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13075-020-02372-z","article-title":"Anti-CD40 antibody KPL-404 inhibits T cell-mediated activation of B cells from healthy donors and autoimmune patients","volume":"23","author":"Marken","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2026.104029_bb0240","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1172\/JCI200320371","article-title":"Therapeutic CD154 antibody for lupus: promise for the future?","volume":"112","author":"Kelsoe","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2026.104029_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102976","article-title":"T follicular helper cells in autoimmune diseases","volume":"134","author":"Wei","year":"2023","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2026.104029_bb0250","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.606024","article-title":"Programmed death-ligand 1 expression potentiates the immune modulatory function of myeloid-derived suppressor cells in systemic lupus erythematosus","volume":"12","author":"Park","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104029_bb0255","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003503","article-title":"PD-1\/PD-L1 governed cross-talk of exhausted CD8(+) T and memory B cells in systemic lupus erythematosus","volume":"10","author":"Wang","year":"2024","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2026.104029_bb0260","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00439-004-1244-1","article-title":"CTLA-4 polymorphisms and systemic lupus erythematosus (SLE): a meta-analysis","volume":"116","author":"Lee","year":"2005","journal-title":"Hum Genet"},{"key":"10.1016\/j.autrev.2026.104029_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.108505","article-title":"ICAM-1 mediated cell-cell adhesion exerts dual roles on human B cell differentiation and IgG production","volume":"26","author":"Liu","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.autrev.2026.104029_bb0270","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/08820139.2019.1624769","article-title":"Elevated blood and urinary ICAM-1 is a biomarker for systemic lupus erythematosus: a systematic review and Meta-analysis","volume":"49","author":"Guo Liu","year":"2020","journal-title":"Immunol Invest"},{"key":"10.1016\/j.autrev.2026.104029_bb0275","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/BOR.0000000000000754","article-title":"Biologics in the treatment of Sjogren's syndrome, systemic lupus erythematosus, and lupus nephritis","volume":"32","author":"Narain","year":"2020","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2026.104029_bb0280","article-title":"The rapid inhibition of B-cell activation markers by belimumab was associated with disease control in systemic lupus erythematosus patients","volume":"14","author":"Wang","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.autrev.2026.104029_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2024.103291","article-title":"Telitacicept: a novel horizon in targeting autoimmunity and rheumatic diseases","volume":"148","author":"Zeng","year":"2024","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2026.104029_bb0290","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.1093\/rheumatology\/keac150","article-title":"Efficacy and safety of obinutuzumab in systemic lupus erythematosus patients with secondary non-response to rituximab","volume":"61","author":"Arnold","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2026.104029_bb0295","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1093\/rheumatology\/keab381","article-title":"Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus","volume":"60","author":"Furie","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2026.104029_bb0300","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1136\/annrheumdis-2017-211388","article-title":"Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles","volume":"76","author":"Chamberlain","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104029_bb0305","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1056\/NEJMoa2118025","article-title":"Trial of anti-BDCA2 antibody Litifilimab for systemic lupus erythematosus","volume":"387","author":"Furie","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104029_bb0310","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1080\/13543784.2023.2212154","article-title":"Litifilimab (BIIB059), a promising investigational drug for cutaneous lupus erythematosus","volume":"32","author":"Cho","year":"2023","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.autrev.2026.104029_bb0315","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/13543784.2025.2473060","article-title":"A focused report on IFN-1 targeted therapies for lupus erythematosus","volume":"34","author":"Bhatt","year":"2025","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.autrev.2026.104029_bb0320","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0140-6736(23)00521-4","article-title":"T-cell-engaging bispecific antibodies in cancer","volume":"402","author":"van de Donk","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2026.104029_bb0325","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41591-022-01765-8","article-title":"Engineered cellular immunotherapies in cancer and beyond","volume":"28","author":"Finck","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2026.104029_bb0330","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12016-025-09114-6","article-title":"Chimeric antigen receptor T cell therapy in systemic lupus erythematosus: mechanisms, clinical advances, and future directions a comprehensive review","volume":"68","author":"Matarneh","year":"2025","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.autrev.2026.104029_bb0335","article-title":"Overcoming Resistance and Relapse in CAR-T and CAR-NK Cell Therapies: From Bench to Bedside","volume":"9","author":"Wang","year":"2026","journal-title":"Research (Wash D C)"},{"key":"10.1016\/j.autrev.2026.104029_bb0340","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.autrev.2026.104029_bb0345","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1038\/s41587-024-02339-4","article-title":"A CAR enhancer increases the activity and persistence of CAR T cells","volume":"43","author":"Rakhshandehroo","year":"2025","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.autrev.2026.104029_bb0350","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.immuni.2016.02.023","article-title":"Distinct signaling of Coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.autrev.2026.104029_bb0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.115973","article-title":"CAR-T cells containing CD28 versus 4-1BB co-stimulatory domains show distinct metabolic profiles in patients","volume":"44","author":"Cook","year":"2025","journal-title":"Cell Rep"},{"key":"10.1016\/j.autrev.2026.104029_bb0360","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.trecan.2022.04.004","article-title":"Mechanisms of T cell exhaustion guiding next-generation immunotherapy","volume":"8","author":"Zebley","year":"2022","journal-title":"Trends Cancer"},{"key":"10.1016\/j.autrev.2026.104029_bb0365","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2026.104029_bb0370","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41467-025-68272-5","article-title":"AI-guided CAR designs and targeted pathway modulation to enhance multi-antigen CAR T cell durability and overcome antigen escape","volume":"17","author":"Ansari","year":"2026","journal-title":"Nat Commun"},{"key":"10.1016\/j.autrev.2026.104029_bb0375","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41422-024-00936-1","article-title":"CAR-toner: an AI-driven approach for CAR tonic signaling prediction and optimization","volume":"34","author":"Qiu","year":"2024","journal-title":"Cell Res"},{"key":"10.1016\/j.autrev.2026.104029_bb0380","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/s41375-025-02518-5","article-title":"Phase 1 clinical trial of B-cell maturation antigen (BCMA) NEX-T\u00ae chimeric antigen receptor (CAR) T cell therapy CC-98633\/BMS-986354 in participants with triple-class exposed multiple myeloma","volume":"39","author":"Ravi","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.autrev.2026.104029_bb0385","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1007\/s12015-025-10923-7","article-title":"Validation of BCMA-CD19 compound CAR-T therapy in SLE overlap syndrome: over 1.5-year follow-up","volume":"21","author":"Wang","year":"2025","journal-title":"Stem Cell Rev Rep"},{"key":"10.1016\/j.autrev.2026.104029_bb0390","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1186\/s12964-024-01894-2","article-title":"Trogocytosis in CAR immune cell therapy: a key mechanism of tumor immune escape","volume":"22","author":"Chen","year":"2024","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.autrev.2026.104029_bb0395","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","article-title":"CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape","volume":"568","author":"Hamieh","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2026.104029_bb0400","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12320","article-title":"CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity","volume":"7","author":"Jacoby","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.autrev.2026.104029_bb0405","article-title":"Expanding the horizon of CAR T cell therapy: from cancer treatment to autoimmune diseases and beyond","volume":"16","author":"Yang","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104029_bb0410","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20240499","article-title":"CD19-directed T cell-engaging antibodies for the treatment of autoimmune disease","volume":"221","author":"Michaelson","year":"2024","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2026.104029_bb0415","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/ard-2024-225785","article-title":"BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial","volume":"83","author":"Wang","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104029_bb0420","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1038\/s41375-024-02444-y","article-title":"Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy","volume":"38","author":"Lei","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.autrev.2026.104029_bb0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2025.103859","article-title":"Chimeric antigen receptor cell therapy: a revolutionary approach transforming cancer treatment to autoimmune disease therapy","volume":"24","author":"Wen","year":"2025","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2026.104029_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102975","article-title":"CAR-NK cells: a promising cellular immunotherapy for cancer","volume":"59","author":"Xie","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.autrev.2026.104029_bb0435","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/ajh.26586","article-title":"A novel adoptive synthetic TCR and antigen receptor (STAR) T-cell therapy for B-cell acute lymphoblastic leukemia","volume":"97","author":"Wang","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.autrev.2026.104029_bb0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114949","article-title":"TCR-mimicking STAR conveys superior sensitivity over CAR in targeting tumors with low-density neoantigens","volume":"43","author":"Huang","year":"2024","journal-title":"Cell Rep"},{"key":"10.1016\/j.autrev.2026.104029_bb0445","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41392-025-02168-0","article-title":"Systemic lupus erythematosus: updated insights on the pathogenesis, diagnosis, prevention and therapeutics","volume":"10","author":"Dai","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.autrev.2026.104029_bb0450","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1136\/ard.2005.044974","article-title":"Decrease of regulatory T cells in patients with systemic lupus erythematosus","volume":"65","author":"Mellor-Pita","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104029_bb0455","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.immuni.2013.09.007","article-title":"Circulating precursor CCR7(lo)PD-1(hi) CXCR5+ CD4+ T cells indicate Tfh cell activity and promote antibody responses upon antigen reexposure","volume":"39","author":"He","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.autrev.2026.104029_bb0460","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/art.24499","article-title":"Th17 and natural Treg cell population dynamics in systemic lupus erythematosus","volume":"60","author":"Yang","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2026.104029_bb0465","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/nm.4148","article-title":"Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus","volume":"22","author":"He","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2026.104029_bb0470","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1136\/annrheumdis-2014-206506","article-title":"Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE","volume":"74","author":"Humrich","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104029_bb0475","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1136\/annrheumdis-2015-207776","article-title":"Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus","volume":"75","author":"von Spee-Mayer","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104029_bb0480","doi-asserted-by":"crossref","DOI":"10.1186\/s12865-015-0070-7","article-title":"IL-17 and IL-23 in lupus nephritis - association to histopathology and response to treatment","volume":"16","author":"Zickert","year":"2015","journal-title":"BMC Immunol"},{"key":"10.1016\/j.autrev.2026.104029_bb0485","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/art.41179","article-title":"Maintenance of efficacy and safety of Ustekinumab through one year in a phase II multicenter, prospective, randomized, double-blind, placebo-controlled crossover trial of patients with active systemic lupus erythematosus","volume":"72","author":"van Vollenhoven","year":"2020","journal-title":"Arthritis & Rheumatism"},{"key":"10.1016\/j.autrev.2026.104029_bb0490","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/S0140-6736(18)32167-6","article-title":"Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study","volume":"392","author":"van Vollenhoven","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2026.104029_bb0495","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1084\/jem.20170580","article-title":"B cell-derived IL-6 initiates spontaneous germinal center formation during systemic autoimmunity","volume":"214","author":"Arkatkar","year":"2017","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2026.104029_bb0500","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1136\/annrheumdis-2012-201310","article-title":"Impact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus","volume":"72","author":"Shirota","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104029_bb0505","doi-asserted-by":"crossref","first-page":"4534","DOI":"10.1182\/blood-2008-12-192559","article-title":"Interleukin-6 aborts lymphopoiesis and elevates production of myeloid cells in systemic lupus erythematosus-prone B6.Sle1.Yaa animals","volume":"113","author":"Maeda","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2026.104029_bb0510","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1172\/JCI117373","article-title":"Interleukin 6 promotes murine lupus in NZB\/NZW F1 mice","volume":"94","author":"Finck","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2026.104029_bb0515","article-title":"c-Myc-driven glycolysis polarizes functional regulatory B cells that trigger pathogenic inflammatory responses","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.autrev.2026.104029_bb0520","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S1359-6101(02)00025-4","article-title":"The role of interleukin-10 in autoimmune disease: systemic lupus erythematosus (SLE) and multiple sclerosis (MS)","volume":"13","author":"Beebe","year":"2002","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.autrev.2026.104029_bb0525","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1172\/JCI119806","article-title":"Interleukin-10 promotes activation-induced cell death of SLE lymphocytes mediated by Fas ligand","volume":"100","author":"Georgescu","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2026.104029_bb0530","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jid.2021.11.031","article-title":"Type I interferons in autoimmunity","volume":"142","author":"Fernandez-Ruiz","year":"2022","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2026.104029_bb0535","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1136\/ard-2023-225445","article-title":"Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials","volume":"83","author":"Baker","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104029_bb0540","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/ard-2022-222748","article-title":"Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus","volume":"82","author":"Morand","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104029_bb0545","doi-asserted-by":"crossref","unstructured":"Kalunian, K. C. et al. A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus. Arthritis & Rheumatism 75, 253\u2013265, doi:https:\/\/doi.org\/10.1002\/art.42392 (2023), Arthritis Rheumatol.","DOI":"10.1002\/art.42392"},{"key":"10.1016\/j.autrev.2026.104029_bb0550","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1136\/annrheumdis-2021-221478","article-title":"Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis","volume":"81","author":"Jayne","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104029_bb0555","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1007\/s40265-021-01604-z","article-title":"Anifrolumab: first approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.autrev.2026.104029_bb0560","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s40265-015-0394-x","article-title":"Targeting interferons in systemic lupus erythematosus: current and future prospects","volume":"75","author":"Mathian","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.autrev.2026.104029_bb0565","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1136\/annrheumdis-2020-219803","article-title":"Experience with milatuzumab, an anti-CD74 antibody against immunomodulatory macrophage migration inhibitory factor (MIF) receptor, for systemic lupus erythematosus (SLE)","volume":"80","author":"Wallace","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104029_bb0570","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.5114\/aoms.2019.85459","article-title":"Levels of the macrophage migration inhibitory factor and polymorphisms in systemic lupus erythematosus: a meta-analysis","volume":"17","author":"Sam","year":"2021","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.autrev.2026.104029_bb0575","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/s41423-023-01049-2","article-title":"B1-cell-produced anti-phosphatidylserine antibodies contribute to lupus nephritis development via TLR-mediated Syk activation","volume":"20","author":"Ma","year":"2023","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.autrev.2026.104029_bb0580","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41584-020-00544-4","article-title":"Toll-like receptor signalling in B cells during systemic lupus erythematosus","volume":"17","author":"Fillatreau","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2026.104029_bb0585","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/cpt.3216","article-title":"Asia-inclusive global development of enpatoran: results of an ethno-bridging study, intrinsic\/extrinsic factor assessments and disease trajectory modeling to inform design of a phase II multiregional clinical trial","volume":"115","author":"Klopp-Schulze","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.autrev.2026.104029_bb0590","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/cpt.2606","article-title":"Applying modeling and simulations for rational dose selection of novel toll-like receptor 7\/8 inhibitor Enpatoran for indications of high medical need","volume":"112","author":"Klopp-Schulze","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.autrev.2026.104029_bb0595","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.842","article-title":"Phase 1 study in healthy participants of the safety, pharmacokinetics, and pharmacodynamics of enpatoran (M5049), a dual antagonist of toll-like receptors 7 and 8","volume":"9","author":"Port","year":"2021","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.autrev.2026.104029_bb0600","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41586-021-03227-6","article-title":"Monocyte-derived S1P in the lymph node regulates immune responses","volume":"592","author":"Baeyens","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2026.104029_bb0605","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/S0140-6736(21)00244-0","article-title":"Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions","volume":"398","author":"McGinley","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2026.104029_bb0610","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1172\/JCI42856","article-title":"Phosphorylation of IRF4 by ROCK2 regulates IL-17 and IL-21 production and the development of autoimmunity in mice","volume":"120","author":"Biswas","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2026.104029_bb0615","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1177\/0961203312436862","article-title":"Administration of fasudil, a ROCK inhibitor, attenuates disease in lupus-prone NZB\/W F1 female mice","volume":"21","author":"Stirzaker","year":"2012","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2026.104029_bb0620","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1136\/annrheumdis-2019-215455","article-title":"Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centre","volume":"78","author":"You","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104029_bb0625","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Wallace","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2026.104029_bb0630","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/art.41811","article-title":"Efficacy, Safety, and Pharmacodynamic Effects of the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial","volume":"73","author":"Isenberg","year":"2021","journal-title":"Arthritis & Rheumatism"},{"key":"10.1016\/j.autrev.2026.104029_bb0635","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-35602-1","article-title":"CKD-506, a novel HDAC6-selective inhibitor, improves renal outcomes and survival in a mouse model of systemic lupus erythematosus","volume":"8","author":"Choi","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.autrev.2026.104029_bb0640","doi-asserted-by":"crossref","first-page":"668","DOI":"10.4049\/immunohorizons.2400028","article-title":"HDAC6 deletion decreases Pristane-induced inflammation","volume":"8","author":"Xu","year":"2024","journal-title":"Immunohorizons"},{"key":"10.1016\/j.autrev.2026.104029_bb0645","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.kint.2018.08.025","article-title":"A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis","volume":"95","author":"Rovin","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.autrev.2026.104029_bb0650","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111289","article-title":"Rapamycin alleviates renal damage in mice with systemic lupus erythematosus through improving immune response and function","volume":"137","author":"Song","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.autrev.2026.104029_bb0655","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-023-07083-9","article-title":"Effects of N-acetylcysteine on systemic lupus erythematosus disease activity and its associated complications: a randomized double-blind clinical trial study","volume":"24","author":"Abbasifard","year":"2023","journal-title":"Trials"},{"key":"10.1016\/j.autrev.2026.104029_bb0660","article-title":"Principles behind SLE treatment with N-acetylcysteine","volume":"4","author":"Nasr","year":"2022","journal-title":"Immunometabolism (Cobham)"},{"key":"10.1016\/j.autrev.2026.104029_bb0665","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0025-6196(25)10643-5","article-title":"Presentation of two bone marrow elements; the tart cell and the L.E. cell","volume":"23","author":"Hargraves","year":"1948","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.autrev.2026.104029_bb0670","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/0002-9343(59)90037-3","article-title":"Systemic lupus erythematosus--disease of an unusual immunologic responsiveness?","volume":"27","author":"Holman","year":"1959","journal-title":"Am J Med"},{"key":"10.1016\/j.autrev.2026.104029_bb0675","doi-asserted-by":"crossref","first-page":"707","DOI":"10.7326\/0003-4819-48-4-707","article-title":"Systemic lupus erythematosus: a complex auto-immune disorder","volume":"48","author":"Dameshek","year":"1958","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2026.104029_bb0680","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/BF02157392","article-title":"Absorption of L. E factor by isolated cell nuclei","volume":"10","author":"Miescher","year":"1954","journal-title":"Experientia"},{"key":"10.1016\/j.autrev.2026.104029_bb0685","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0140-6736(59)90493-3","article-title":"Immunological studies in nephritis","volume":"2","author":"Freedman","year":"1959","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2026.104029_bb0690","first-page":"205","article-title":"Immunohistochemical study of lesions in rheumatic fever, systemic lupus erythematosus, and rheumatoid arthritis","volume":"6","author":"Vazquez","year":"1957","journal-title":"Lab Invest"},{"key":"10.1016\/j.autrev.2026.104029_bb0695","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1084\/jem.106.2.191","article-title":"Role of gamma globulins in pathogenesis of renal lesions in systemic lupus erythematosus and chronic membranous glomerulonephritis, with an observation on the lupus erythematosus cell reaction","volume":"106","author":"Mellors","year":"1957","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2026.104029_bb0700","doi-asserted-by":"crossref","first-page":"476","DOI":"10.4049\/jimmunol.80.6.476","article-title":"Identification of the nuclear component of the interaction of lupus erythematosus globulin and nuclei","volume":"80","author":"Friou","year":"1958","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2026.104029_bb0705","doi-asserted-by":"crossref","first-page":"572","DOI":"10.3181\/00379727-96-23544","article-title":"A DNA-reacting factor in serum of a patient with lupus erythematosus diffusus","volume":"96","author":"Ceppellini","year":"1957","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.autrev.2026.104029_bb0710","first-page":"243","article-title":"Demonstration in the blood of patients with disseminated lupus erythematosus a substance determining a precipitation reaction with desoxyribonucleic acid","volume":"245","author":"Seligmann","year":"1957","journal-title":"C R Hebd Seances Acad Sci"},{"key":"10.1016\/j.autrev.2026.104029_bb0715","doi-asserted-by":"crossref","first-page":"464","DOI":"10.4049\/jimmunol.96.3.464","article-title":"Characteristics of a soluble nuclear antigen precipitating with sera of patients with systemic lupus erythematosus","volume":"96","author":"Tan","year":"1966","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2026.104029_bb0720","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4049\/jimmunol.102.1.117","article-title":"Characterization of a soluble cytoplasmic antigen reactive with sera from patients with systemic lupus erythematosus","volume":"102","author":"Clark","year":"1969","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2026.104029_bb0725","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.4049\/jimmunol.107.5.1281","article-title":"Characterization of a soluble nuclear ribonucleoprotein antigen reactive with SLE sera","volume":"107","author":"Mattioli","year":"1971","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2026.104029_bb0730","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/art.1780170413","article-title":"Heterogeneity of RNA protein antigens reactive with sera of patients with systemic lupus erythematosus. Description of a cytoplasmic nonribosomal antigen","volume":"17","author":"Mattioli","year":"1974","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2026.104029_bb0735","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1016\/0140-6736(90)91374-J","article-title":"Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor","volume":"335","author":"Galli","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2026.104029_bb0740","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.1073\/pnas.87.11.4120","article-title":"Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H)","volume":"87","author":"McNeil","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2026.104029_bb0745","doi-asserted-by":"crossref","DOI":"10.1016\/j.ard.2025.04.008","article-title":"Novel IgG and IgA autoantibodies validated in two independent cohorts are associated with disease activity and determine organ manifestations in systemic lupus erythematosus: implications for anti-LIN28A, anti-HMGN5, anti-IRF5, and anti-TGIF1","author":"Lindblom","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104029_bb0750","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1136\/ard-2023-225369","article-title":"Risk of flare and damage accrual after tapering glucocorticoids in modified serologically active clinically quiescent patients with systemic lupus erythematosus: a multinational observational cohort study","volume":"83","author":"Katsumata","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104029_bb0755","doi-asserted-by":"crossref","first-page":"5517","DOI":"10.1093\/rheumatology\/keab149","article-title":"Low-dose glucocorticoids should be withdrawn or continued in systemic lupus erythematosus? A systematic review and meta-analysis on risk of flare and damage accrual","volume":"60","author":"Ji","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2026.104029_bb0760","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1515\/rir-2025-0017","article-title":"2025 Chinese guidelines for the diagnosis and treatment of systemic lupus erythematosus","volume":"6","author":"Zhao","year":"2025","journal-title":"Rheumatol Immunol Res"},{"key":"10.1016\/j.autrev.2026.104029_bb0765","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1177\/09612033221074184","article-title":"IgA anti-dsDNA antibodies: a neglected serological parameter in systemic lupus erythematosus","volume":"31","author":"Lee","year":"2022","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2026.104029_bb0770","article-title":"American College of Rheumatology (ACR) Guideline for the Treatment of Systemic Lupus Erythematosus","author":"Sammaritano","year":"2025","journal-title":"Arthritis & Rheumatism"},{"key":"10.1016\/j.autrev.2026.104029_bb0775","doi-asserted-by":"crossref","first-page":"6071","DOI":"10.1016\/j.cell.2024.08.025","article-title":"Neoself-antigens are the primary target for autoreactive T cells in human lupus","volume":"187","author":"Mori","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.autrev.2026.104029_bb0780","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.molmed.2012.01.008","article-title":"The DWEYS peptide in systemic lupus erythematosus","volume":"18","author":"Bosch","year":"2012","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.autrev.2026.104029_bb0785","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.imlet.2007.12.016","article-title":"An antibody-based construct carrying DNA-mimotope and targeting CR1(CD35) selectively suppresses human autoreactive B-lymphocytes","volume":"116","author":"Voynova","year":"2008","journal-title":"Immunol Lett"},{"key":"10.1016\/j.autrev.2026.104029_bb0790","doi-asserted-by":"crossref","first-page":"8859","DOI":"10.1021\/acs.jmedchem.6b00694","article-title":"Amending HIV drugs: a novel small-molecule approach to target lupus an ti-DNA antibodies","volume":"59","author":"VanPatten","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.autrev.2026.104029_bb0795","doi-asserted-by":"crossref","unstructured":"Bloom, O. et al. Generation of a unique small molecule peptidomimetic that neutralizes lupus autoantibody activity. Proc Natl Acad Sci U S A 108, 10255\u201310259, doi:https:\/\/doi.org\/10.1073\/pnas.1103555108 (2011).","DOI":"10.1073\/pnas.1103555108"},{"key":"10.1016\/j.autrev.2026.104029_bb0800","first-page":"20119","article-title":"Autoantigenic peptide and immunomodulator codelivery system for rheumatoid arthritis treatment by reestablishing immune tolerance","volume":"16","author":"Mai","year":"2024","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/j.autrev.2026.104029_bb0805","doi-asserted-by":"crossref","first-page":"e314","DOI":"10.1016\/S2665-9913(24)00035-3","article-title":"Proteinase 3-specific antineutrophil cytoplasmic antibody-associated vasculitis","volume":"6","author":"Falde","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2026.104029_bb0810","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.cbpa.2017.07.001","article-title":"Synthetic antibody mimics for the inhibition of protein-ligand interactions","volume":"40","author":"Hau\u00dfner","year":"2017","journal-title":"Curr Opin Chem Biol"},{"key":"10.1016\/j.autrev.2026.104029_bb0815","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.clim.2018.08.012","article-title":"Indoleamine-2,3-dioxygenase in murine and human systemic lupus erythematosus: down-regulation by the tolerogeneic peptide hCDR1","volume":"197","author":"Sthoeger","year":"2018","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2026.104029_bb0820","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2015-000104","article-title":"Safety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosus: results of phase II study","volume":"2","author":"Urowitz","year":"2015","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.autrev.2026.104029_bb0825","doi-asserted-by":"crossref","first-page":"e395","DOI":"10.1111\/j.1365-2567.2008.02988.x","article-title":"The role of dendritic cells in the mechanism of action of a peptide that ameliorates lupus in murine models","volume":"128","author":"Sela","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.autrev.2026.104029_bb0830","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.clim.2008.12.009","article-title":"B-cell activating factor (BAFF) plays a role in the mechanism of action of a tolerogenic peptide that ameliorates lupus","volume":"131","author":"Parameswaran","year":"2009","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2026.104029_bb0835","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.clim.2005.09.003","article-title":"Amelioration of SLE-like manifestations in (NZBxNZW)F1 mice following treatment with a peptide based on the complementarity determining region 1 of an autoantibody is associated with a down-regulation of apoptosis and of the pro-apoptotic factor JNK kinase","volume":"117","author":"Rapoport","year":"2005","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2026.104029_bb0840","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s10875-004-6245-2","article-title":"A peptide based on the complementarity determining region 1 of a human monoclonal autoantibody ameliorates spontaneous and induced lupus manifestations in correlation with cytokine immunomodulation","volume":"24","author":"Luger","year":"2004","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.autrev.2026.104029_bb0845","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.718359","article-title":"Cellular and molecular phenotypes of pConsensus peptide (pCons) induced CD8(+) and CD4(+) regulatory T cells in lupus","volume":"12","author":"Singh","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104029_bb0850","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-019-2038-0","article-title":"ALW peptide ameliorates lupus nephritis in MRL\/lpr mice","volume":"21","author":"Wang","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2026.104029_bb0855","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1093\/rheumatology\/ker231","article-title":"Antigen-specific immature dendritic cell vaccine ameliorates anti-dsDNA antibody-induced renal damage in a mouse model","volume":"50","author":"Xia","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2026.104029_bb0860","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1182\/blood.V100.1.174","article-title":"Antigen-bearing immature dendritic cells induce peptide-specific CD8(+) regulatory T cells in vivo in humans","volume":"100","author":"Dhodapkar","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2026.104029_bb0865","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-45056-x","article-title":"Smith-specific regulatory T cells halt the progression of lupus nephri tis","volume":"15","author":"Eggenhuizen","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.autrev.2026.104029_bb0870","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.autrev.2026.104029_bb0875","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104029_bb0880","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104029_bb0885","doi-asserted-by":"crossref","first-page":"6317","DOI":"10.1172\/JCI138416","article-title":"Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris","volume":"130","author":"Lee","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2026.104029_bb0890","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/s41587-022-01637-z","article-title":"Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells","volume":"41","author":"Oh","year":"2023","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.autrev.2026.104029_bb0895","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.molmed.2025.06.003","article-title":"10 years in lupus - progress, but not enough","volume":"32","author":"Morand","year":"2026","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.autrev.2026.104029_bb0900","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/imr.13015","article-title":"On the road to eliminating long-lived plasma cells-\u201care we there yet?\u201d","volume":"303","author":"Markmann","year":"2021","journal-title":"Immunol Rev"},{"key":"10.1016\/j.autrev.2026.104029_bb0905","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/eji.201444993","article-title":"Selection and depletion of plasma cells based on the specificity of the secreted antibody","volume":"45","author":"Taddeo","year":"2015","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.autrev.2026.104029_bb0910","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/mt.2016.165","article-title":"Like angler fish, CAARs lure their prey","volume":"24","author":"Galy","year":"2016","journal-title":"Mol Ther"},{"key":"10.1016\/j.autrev.2026.104029_bb0915","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26030929","article-title":"Advances in targeted therapy for systemic lupus erythematosus: current treatments and novel approaches","volume":"26","author":"Saegusa","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2026.104029_bb0920","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.104911","article-title":"Dynamically modeling the effective range of IL-2 dosage in the treatment of systemic lupus erythematosus","volume":"25","author":"Gao","year":"2022","journal-title":"iScience"},{"key":"10.1016\/j.autrev.2026.104029_bb0925","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/s41551-021-00797-8","article-title":"Site-specific PEGylation of interleukin-2 enhances immunosuppression via the sustained activation of regulatory T cells","volume":"5","author":"Zhang","year":"2021","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.autrev.2026.104029_bb0930","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2025.100306","article-title":"Targeted regulatory T cell activation by site-specific PEGylated interleukin-2 mitigates autoimmune inflammation","volume":"11","author":"Ikeda","year":"2025","journal-title":"J Transl Autoimmun"},{"key":"10.1016\/j.autrev.2026.104029_bb0935","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.gpb.2015.09.001","article-title":"Autoantigen microarray for high-throughput autoantibody profiling in systemic lupus erythematosus","volume":"13","author":"Zhu","year":"2015","journal-title":"Genomics Proteomics Bioinformatics"},{"key":"10.1016\/j.autrev.2026.104029_bb0940","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/jimmun\/vkae025","article-title":"Characterization of autoantibody profiles in clusters of systemic lupus erythematosus using a novel autoantigen discovery technology","volume":"214","author":"DiCillo","year":"2025","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2026.104029_bb0945","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1136\/ard-2023-224537","article-title":"Extracting immunological and clinical heterogeneity across autoimmune rheumatic diseases by cohort-wide immunophenotyping","volume":"83","author":"Tanaka","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104029_bb0950","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/ard-2024-226142","article-title":"CD19-CAR T-cell therapy induces deep tissue depletion of B cells","volume":"84","author":"Tur","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104029_bb0955","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","article-title":"Current understanding and management of CAR T cell-associated toxicities","volume":"21","author":"Brudno","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.autrev.2026.104029_bb0960","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.tips.2023.04.005","article-title":"Artificial intelligence-driven drug development against autoimmune diseases","volume":"44","author":"Moingeon","year":"2023","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.autrev.2026.104029_bb0965","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103294","article-title":"Current state and completeness of reporting clinical prediction models using machine learning in systemic lupus erythematosus: a systematic review","volume":"22","author":"Mungu\u00eda-Realpozo","year":"2023","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2026.104029_bb0970","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105785","article-title":"Advances in precision medicine for lupus nephritis: biomarker- and AI-driven diagnosis and treatment response prediction and targeted therapies","volume":"117","author":"Shang","year":"2025","journal-title":"EBioMedicine"},{"key":"10.1016\/j.autrev.2026.104029_bb0975","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.inffus.2018.09.012","article-title":"Machine learning for integrating data in biology and medicine: principles, practice, and opportunities","volume":"50","author":"Zitnik","year":"2019","journal-title":"Inf Fusion"},{"key":"10.1016\/j.autrev.2026.104029_bb0980","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1038\/s41591-022-01981-2","article-title":"Multimodal biomedical AI","volume":"28","author":"Acosta","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2026.104029_bb0985","doi-asserted-by":"crossref","first-page":"e485","DOI":"10.1016\/S2665-9913(20)30168-5","article-title":"Disease-associated and patient-specific immune cell signatures in juvenile-onset systemic lupus erythematosus: patient stratification using a machine-learning approach","volume":"2","author":"Robinson","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2026.104029_bb0990","doi-asserted-by":"crossref","unstructured":"Toro-Dom\u00ednguez, D. et al. Stratification of systemic lupus erythematosus patients into three groups of disease activity progression according to longitudinal gene expression. Arthritis & Rheumatism 70, 2025\u20132035, doi:https:\/\/doi.org\/10.1002\/art.40653 (2018), Arthritis Rheum.","DOI":"10.1002\/art.40653"},{"key":"10.1016\/j.autrev.2026.104029_bb0995","article-title":"Analysis of transcriptomic features reveals molecular endotypes of SLE with clinical implications","volume":"15","author":"Hubbard","year":"2023","journal-title":"Genome Med"},{"key":"10.1016\/j.autrev.2026.104029_bb1000","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbac332","article-title":"Scoring personalized molecular portraits identify systemic lupus erythematosus subtypes and predict individualized drug responses, symptomatology and disease progression","volume":"23","author":"Toro-Dom\u00ednguez","year":"2022","journal-title":"Brief Bioinform"},{"key":"10.1016\/j.autrev.2026.104029_bb1005","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100291","article-title":"Adults with systemic lupus exhibit distinct molecular phenotypes in a cross-sectional study","volume":"20","author":"Guthridge","year":"2020","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.autrev.2026.104029_bb1010","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1093\/rheumatology\/keac625","article-title":"Deep stratification by transcriptome molecular characters for precision treatment of patients with systemic lupus erythematosus","volume":"62","author":"Qiao","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2026.104029_bb1015","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1136\/ard-2022-223808","article-title":"Machine learning identifies clusters of longitudinal autoantibody profiles predictive of systemic lupus erythematosus disease outcomes","volume":"82","author":"Choi","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104029_bb1020","doi-asserted-by":"crossref","DOI":"10.1093\/jamiaopen\/ooaf072","article-title":"A fair machine learning model to predict flares of systemic lupus erythematosus","volume":"8","author":"Li","year":"2025","journal-title":"JAMIA Open"},{"key":"10.1016\/j.autrev.2026.104029_bb1025","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1136\/annrheumdis-2020-219069","article-title":"Lupus or not? SLE risk probability index (SLERPI): a simple, clinician-friendly machine learning-based model to assist the diagnosis of systemic lupus erythematosus","volume":"80","author":"Adamichou","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104029_bb1030","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2025-006009","article-title":"Systemic lupus erythematosus damage risk index (SLE-DRI): a simple machine learning-based tool for identifying patients at risk for early organ damage","volume":"11","author":"Garantziotis","year":"2025","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2026.104029_bb1035","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1093\/rheumatology\/keaf215","article-title":"Unsupervised machine learning identifies distinct SLE patient endotypes with differential response to belimumab","volume":"64","author":"Depascale","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2026.104029_bb1040","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2025.110782","article-title":"Machine learning-assisted tacrolimus dose optimization in childhood- onset systemic lupus erythematosus through population pharmacokinetic modeling","volume":"196","author":"Liang","year":"2025","journal-title":"Comput Biol Med"},{"key":"10.1016\/j.autrev.2026.104029_bb1045","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70146","article-title":"Mechanistic evaluation of anti-CD19 CAR-T cell therapy repurposed in systemic lupus erythematosus using a quantitative systems pharmacology model","volume":"18","author":"Park","year":"2025","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.autrev.2026.104029_bb1050","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","article-title":"Accurate structure prediction of biomolecular interactions with AlphaFold 3","volume":"630","author":"Abramson","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2026.104029_bb1055","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/s41586-023-06415-8","article-title":"De novo design of protein structure and function with RFdiffusion","volume":"620","author":"Watson","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2026.104029_bb1060","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1126\/science.add2187","article-title":"Robust deep learning-based protein sequence design using ProteinMPNN","volume":"378","author":"Dauparas","year":"2022","journal-title":"Science (New York, NY)"},{"key":"10.1016\/j.autrev.2026.104029_bb1065","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41586-025-09721-5","article-title":"Atomically accurate de novo design of antibodies with RFdiffusion","volume":"649","author":"Bennett","year":"2026","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2026.104029_bb1070","doi-asserted-by":"crossref","first-page":"7206","DOI":"10.1016\/j.cell.2025.10.006","article-title":"Generation of antigen-specific paired-chain antibodies using large language models","volume":"188","author":"Wasdin","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.autrev.2026.104029_bb1075","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/s41586-025-09442-9","article-title":"The virtual lab of AI agents designs new SARS-CoV-2 nanobodies","volume":"646","author":"Swanson","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2026.104029_bb1080","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41592-025-02913-x","article-title":"ImmunoMatch learns and predicts cognate pairing of heavy and light immunoglobulin chains","volume":"23","author":"Guo","year":"2026","journal-title":"Nat Methods"},{"key":"10.1016\/j.autrev.2026.104029_bb1085","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1016\/j.ymthe.2025.07.044","article-title":"Computational structural optimization enhances IL13R\u03b12 - B7-H3 tandem CAR T cells to overcome antigen-heterogeneity-mediated tumor escape","volume":"33","author":"Meehl","year":"2025","journal-title":"Mol Ther"},{"key":"10.1016\/j.autrev.2026.104029_bb1090","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/annrheumdis-2020-216924","article-title":"2019 update of the joint European league against rheumatism and European renal association-European Dialysis and transplant association (EULAR\/ERA-EDTA) recommendations for the management of lupus nephritis","volume":"79","author":"Fanouriakis","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104029_bb1095","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1681\/ASN.2008101028","article-title":"Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis","volume":"20","author":"Appel","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.autrev.2026.104029_bb1100","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1093\/rheumatology\/kead348","article-title":"Glucocorticoid treatment in SLE is associated with infections, comorbidities and mortality-a national cohort study","volume":"63","author":"Frodlund","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2026.104029_bb1105","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1232244","article-title":"Efficacy and safety of immunosuppressive agents for adults with lupus nephritis: a systematic review and network meta-analysis","volume":"14","author":"Jiang","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104029_bb1110","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1474-4422(24)00028-0","article-title":"Comparative effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis (PROMISE-MG): a prospective cohort study","volume":"23","author":"Narayanaswami","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2026.104029_bb1115","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/rheumatology\/keaa478","article-title":"The risk of infections in adult patients with systemic lupus erythematosus: systematic review and meta-analysis","volume":"60","author":"Pego-Reigosa","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2026.104029_bb1120","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9092709","article-title":"Glucocorticoids in systemic lupus erythematosus. Ten questions and some issues","volume":"9","author":"Porta","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.autrev.2026.104029_bb1125","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/nrclinonc.2018.32","article-title":"Immunotherapy: CAR T cell therapy efficacious against B-ALL across age groups","volume":"15","author":"Sidaway","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.autrev.2026.104029_bb1130","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41573-024-00959-8","article-title":"Sequential immunotherapy: towards cures for autoimmunity","volume":"23","author":"Ram\u00edrez-Valle","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.autrev.2026.104029_bb1135","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1056\/NEJMoa2401361","article-title":"Risk of second tumors and T-cell lymphoma after CAR T-cell therapy","volume":"390","author":"Hamilton","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104029_bb1140","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa2401530","article-title":"Indolent CD4+ CAR T-cell lymphoma after Cilta-cel CAR T-cell therapy","volume":"390","author":"Ozdemirli","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104029_bb1145","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1056\/NEJMe2405538","article-title":"T-cell Cancer after CAR T-cell therapy","volume":"390","author":"Mitchell","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104029_bb1150","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1056\/NEJMoa2411507","article-title":"CD4+ T-cell lymphoma harboring a chimeric antigen receptor integration in TP53","volume":"392","author":"Perica","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104029_bb1155","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1056\/NEJMc2408029","article-title":"T-cell neoplasms after B-cell neoplasms - the pre-CAR T-cell era","volume":"391","author":"Dores","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104029_bb1160","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1186\/s12967-025-06400-x","article-title":"Surveying local CAR T-cell manufacturing processes to facilitate standardization and expand accessibility","volume":"23","author":"Gupta","year":"2025","journal-title":"J Transl Med"},{"key":"10.1016\/j.autrev.2026.104029_bb1165","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1182\/bloodadvances.2023011992","article-title":"Early predictive factors of failure in autologous CAR T-cell manufacturing and\/or efficacy in hematologic malignancies","volume":"8","author":"Baguet","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.autrev.2026.104029_bb1170","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104029_bb1175","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1454747","article-title":"Cutting-edge approaches to B-cell depletion in autoimmune diseases","volume":"15","author":"Robinson","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104029_bb1180","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1136\/ard-2024-225727","article-title":"B-cell depletion in autoimmune diseases","volume":"83","author":"Schett","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104029_bb1185","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/ncprheum0895","article-title":"Nature and functions of autoantibodies","volume":"4","author":"Elkon","year":"2008","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1016\/j.autrev.2026.104029_bb1190","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1046\/j.1365-2249.2003.02108.x","article-title":"Glomerular deposition of C1q and anti-C1q antibodies in mice following injection of antimouse C1q antibodies","volume":"132","author":"Trouw","year":"2003","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2026.104029_bb1195","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1172\/JCI78084","article-title":"Autoantibodies in systemic autoimmune diseases: specificity and pathogenicity","volume":"125","author":"Suurmond","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2026.104029_bb1200","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.676082","article-title":"IFN-I mediates lupus nephritis from the beginning to renal fibrosis","volume":"12","author":"Ding","year":"2021","journal-title":"Front Immunol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226000431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226000431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T14:30:27Z","timestamp":1775053827000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997226000431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":240,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1568997226000431"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104029","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Precision immunotherapies for systemic lupus erythematosus: From pathogenic targets to translational horizons","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104029"}}